La chaîne d'options affiche les données clés des options sur actions de Lipella Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Lipella Pharmaceuticals..

Lipella Pharmaceuticals (NASDAQ:LIPO) Stock, Chaîne d'Options

Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals Inc

Lipocine Inc

Two executives with ties to President Donald Trump and Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) have a new SPAC offering targeting <a href="https://www.benzinga.com/news/ipos/25/03/44367379/global-client-advisory-group-affiliate-files-for-175-million-ipo-targeting-crypto-digital-security-ventures">the cryptocurrency market.</a>
With several stocks soaring on recent crypto-related mergers, could this be a SPAC to watch?
The SPAC Offering: On Thursday, Renatus Tactical Acquisition Corp I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTACU#NASDAQ">RTACU</a>) began trading. The units consist of one common share (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTAC#NASDAQ">RTAC</a>) and one-half of a redeemable warrant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTAW#NASDAQ">RTAW</a>).
After announcing a 17.5 million offering at $10 per unit to raise $175 million, the offering was upsized to 21 million shares <a href="https://www.businesswire.com/news/home/20250513920321/en/Renatus-Tactical-Acquisition-Corp-I-Announces-Pricing-of-Upsized-%24210-Million-Initial-Public-Offering">raising </a>$210 million.
While SPACs have received less attention in recent years, this particular blank check company, given its two names attached, could quickly attract investors&#8217; attention.
Among the names involved in the sponsor companies of the SPAC deal are Eric Swider and Devin Nunes. Swider is the former CEO of Digital World Acquisition Corporation. The company, referred to as DWAC, was a SPAC that took Trump's media company Trump Media &amp; Technology Group public. 
Swider and Nunes currently <a href="https://ir.tmtgcorp.com/corporate-governance/board-of-directors/">serve </a>as director and CEO of Trump Media &amp; Technology Group, respectively. For the new SPAC, Swider <a href="https://www.sec.gov/edgar/browse/?CIK=0002035173">serves</a> as CEO while Nunes is chairman.
SPAC expert and Accelerate CEO Julian Klymochko <a href="https://x.com/JulianKlymochko/status/1922987358086893655">highlighted </a>the offering in a tweet Thursday.
"The former CEO of $DWAC, Eric Swider, along with the current CEO of $DJT, Devin Nunes, launched a new SPAC, Renatus Tactical Acquisition I. It IPO'd today. Its focus is on the crypto industry in the U.S. It's one to watch!" Klymochko tweeted.
Read Also: <a href="https://www.benzinga.com/24/12/42498758/truth-social-ceo-nunes-to-head-trumps-intelligence-advisory-board">Truth Social CEO Nunes to Head Trump&#8217;s Intelligence Advisory Board</a>
The SPAC Target Market: The SPAC could target a merger in any industry, sector or geographic region. However, the prospectus indicates a focus on finding a company in the cryptocurrency or blockchain space in the United States. Data security and dual-use technologies are also listed as potential target areas for a deal.
"We intend to capitalize on the ability of our management team to identify, acquire and operate a business or businesses that can benefit from our management team's established global relationships, sector expertise and active management and operating experience," the prospectus reads.
The SPAC is targeting a company valued between $500 million and $5 billion.
The prospectus also highlights Trump's positive push for cryptocurrency and the growing market opportunity for Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and other cryptocurrencies. It recalls the recent executive order to create a strategic Bitcoin reserve by <a href="https://www.benzinga.com/25/03/44183572/trump-establishes-strategic-bitcoin-reserve-funded-by-forfeited-assets-i-made-the-promise">stockpiling cryptocurrency assets</a>. 
Why It's Important: The timing of the public offering could be a strong setup for the management team and investors with several recent crypto-related merger announcements seeing shares trade significantly higher and receive increased attention.
Here are some of the recent deals:
<ul class="wp-block-list">
<li>Bitcoin holding company Twenty One <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44975441/cantor-fitzgerald-backed-twenty-one-launches-strategy-rival-at-3-billion-valuation">announced a SPAC merger</a> with Cantor Equity Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEP#NASDAQ">CEP</a>) with a target of holding 42,000 Bitcoin. The merger includes backing from Tether, SoftBank Group and Jack Mallers, who will serve as CEO. After the merger, the company will trade as "XXI" on the Nasdaq and could be one of the largest public holders of Bitcoin.</li>
<li>Asset Entities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) <a href="https://www.benzinga.com/news/contracts/25/05/45260992/asset-entities-stock-rockets-higher-on-merger-deal-to-form-bitcoin-treasury-company">announced a merger</a> with Strive Asset Management to become a public Bitcoin holding company on the Nasdaq.</li>
<li>Nakamoto Holdings <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45352237/nakamoto-holdings-raises-710m-merges-with-kindlymd-to-build-bitcoin-treasury-holding-company">announced a merger</a> with Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) in a deal that will see the newly formed company be a Bitcoin holding company. Nakamoto comes from the mind of Bitcoin Magazine CEO and Trump crypto advisor David Bailey, who will serve as CEO.</li>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) recently <a href="https://www.benzinga.com/news/small-cap/25/05/45347101/gryphon-digital-to-take-trump-affiliated-american-bitcoin-public-in-merger-deal-stock-soars">announced a merger </a>with American Bitcoin, a subsidiary of Hut 8 Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>). American Bitcoin was launched in collaboration between Hut 8 and Eric Trump earlier this year. The new company will trade on the Nasdaq with the ticker "ABTC."</li>
</ul>
While not all of these were SPAC mergers, these stocks all saw shares trade higher on deal announcements, illustrating investors appetite for crypto-related mergers.
Price Action: Renatus Tactical Acquisition Corp units trade at $10.88 Thursday and have traded between $10.60 and $10.99 since going public.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/21/12/24526791/5-things-you-might-not-know-about-devin-nunes-ceo-of-trump-media-technology-group">5 Things You Might Not Know About Devin Nunes, CEO Of Trump Media &amp; Technology Group</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

IPOs

$BTC

ASST

GRYP

KDLY

RTAC

RTACU

RTAW

Trump Insiders Want A Piece Of Crypto, SPAC Action: Is A Merger Coming?

Deere &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) shares are trading higher at the last check on Thursday after the company reported second-quarter net sales and revenue fell 16% year-over-year to $12.76 billion, topping the consensus <a href="https://www.benzinga.com/news/earnings/25/05/45441833/deere-shares-rise-after-q2-beat-despite-steep-sales-declines-across-segments" target="_blank" rel="noreferrer noopener">estimate of $10.79 billion</a>.
The company expects FY25 net income to be between $4.75 billion-$5.5 billion <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">(prior $5 billion and $5.5 billion)</a>.
Goldman Sachs analyst Jerry Revich reiterated a Buy rating <a target="_blank" href="https://www.benzinga.com/quote/DE/analyst-ratings" rel="noreferrer noopener">and price forecast of $583</a>.
The analyst&#8217;s rating reflects expected Machinery capital stock growth, end of new equipment destocking, faster Precision Ag adoption, and reduced tariff margin risk.
The analyst views Deere's second-quarter results as consistent with adjusted expectations following the Machinery earnings announcement.
This reflects a margin guidance reduction of about 100 bps, likely due to tariffs impacting Construction &amp; Forestry, and a second-quarter earnings beat on 35% decremental margins (vs. GS: 46% estimate).
Also, the analyst highlighted dealers increasing inventories ahead of normal seasonality for the first time in seven quarters, suggesting the end of destocking.
Investors can gain exposure to the stock via iShares MSCI Agriculture Producers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEGI#NYSE">VEGI</a>) and Global X AgTech &amp; Food Innovation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROP#NASDAQ">KROP</a>).
Price Action: DE shares are up 3.08% at $522.15 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45430835/us-stocks-likely-to-open-lower-after-sp-500s-three-day-winning-streak-many-uncertainties-remain-says-expert" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Lower After S&amp;P 500&#8217;s Three-Day Winning Streak: &#8216;&#8230;Many Uncertainties Remain,&#8217; Says Expert</a></li>
</ul>
Image: Shutterstock

Equities

Large Cap

Movers

KROP

VEGI

Green Light For Deere: Analyst Sees Growth Ahead Despite Tariff Concerns

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) recent surge to $104,000 has been driven primarily <a href="https://www.benzinga.com/money/bitcoin-price-prediction">by spot accumulation</a> and a notable reduction in sell-side pressure, according to Glassnode's market report released Thursday.
What Happened: A key short-term support level has emerged around $93,000–$95,000, with both on-chain and exchange data suggesting that recent buyers are defending this cost basis zone.
&#8220;A key accumulation zone emerged between $93k and $95k,&#8221; the report <a href="https://insights.glassnode.com/the-week-onchain-week-19-2025/?utm_campaign=WoC_19_25&amp;utm_medium=email&amp;utm_source=newsletter">notes</a>, adding that this range aligns closely with the Short-Term Holder (STH) cost basis, which includes investors who entered the market in the past five months.
Glassnode analysts highlight that this zone is likely to act as a structural support during pullbacks. "This range&#8230; represents a demand zone where investors are likely to see value once again," they wrote.
Supporting this, net buying pressure has intensified on U.S. exchange Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), while selling on Binance has sharply declined. "Coinbase has experienced a regime of consistent net buying&#8230; Binance markets have transitioned from intense net selling&#8230; to a milder -$9M daily today."
In derivatives markets, perpetual futures open interest has dropped by 10% from its peak, signaling a short squeeze and cleansing of excessive short-side leverage. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45438872/want-to-copytrade-the-trump-linked-world-liberty-financial-portfolio-dont-be-so-sure">Want To Copytrade The Trump-Linked World Liberty Financial Portfolio? Don&#8217;t Be So Sure</a>
WHy It MattersL This positions the market for a more sustainable uptrend.
"These types of shakeouts are characteristic of healthy resets&#8230; often seen during the early phases of a new market trend," the report states.
While ETF inflows have slowed from a peak of $389 million/day to around $58 million/day, demand remains strong. Glassnode points out that this institutional participation reflects a longer-term conviction in Bitcoin, echoing inflow patterns from earlier rallies in 2024.
Options market data also shows traders leaning bullish. 
The 1-month 25 Delta Skew stands at -6.1%, indicating traders are paying more for calls than puts, a classic sign of upside speculation.
The report further states that Bitcoin's upward momentum is well-supported. 
As long as the cost basis support zone holds and derivatives markets continue to stabilize, the rally may remain intact even as the asset approaches its all-time high near $109,000.
Read Next: 
<ul class="wp-block-list">
<li><a style="font-weight: bold;" href="https://www.benzinga.com/markets/cryptocurrency/25/05/45433455/arthur-hayes-predicts-bitcoin-to-hit-1-million-by-2028">Arthur Hayes Predicts Bitcoin To Hit $1 Million By 2028</a></li>
</ul>
Image: Shutterstock

News

COIN

Bitcoin Rally Supported By $95,000 Cost Basis Zone: Report

Goldman Sachs analyst James Yaro discusses the performance of retail <a href="https://www.benzinga.com/crypto" target="_blank" rel="noreferrer noopener">brokers and investment bank stocks in his coverage</a>.
Retail Broker Sector: In particular, the analyst noted that Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) and Interactive Brokers Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) witnessed an average rise of about 35% since April 1, 2025, significantly outperforming the S&amp;P 500 by 31 percentage points.
Yaro writes that this indicates ongoing optimism about the retail trading environment, supported by robust April metrics.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/25/05/45441997/coinbase-hit-by-data-breach-refuses-to-pay-20m-ransom" rel="noreferrer noopener">Coinbase Hit By Data Breach, Refuses To Pay $20M Ransom</a>
The analyst says he remains positive on retail trading, noting that current levels are still considerably below historical highs when adjusted for account growth.
Yaro estimates 12%/5% revenue and EPS CAGRs from 2024-2027, driven by robust account acquisition, strong assets gathering, and a cyclically supportive retail trading environment.
Yaro projects compound annual growth rates (CAGRs) of 12% for revenue and 5% for EPS from 2024 to 2027, based on strong new account acquisition, robust asset gathering, and a cyclically supportive retail trading environment.
Investment Bank Sector: Stocks are up 7% since the same date, slightly outperforming the S&amp;P 500 by three percentage points, adds the analyst.
Yaro says that the cyclical recovery in investment banking appears to have been delayed again, with disclosed industry M&amp;A fees down 34% quarter-to-date year-over-year and ECM/DCM volumes falling 44%/41% in April year-over-year.
The analyst adds that the market likely needs more concrete signs of an investment banking recovery for the stocks to continue outperforming from this point on.
Given the base case scenario of limited mergers and acquisitions activity this year, the analyst anticipates a modest 3% year-over-year increase in total revenue for 2025.
In the near term, the analyst&#8217;s model forecasts a 2% quarter-over-quarter revenue decline for the second quarter of 2025.
Nevertheless, Yaro maintains a positive outlook for the medium term, projecting revenue growth of 16% in 2026 and 10% in 2027.
Overall, he views companies with more consistent structural growth prospects as positive, including Buy-rated Houlihan Lokey, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLI#NYSE">HLI</a>), HOOD, and IBKR.
Yaro also favors companies with an underappreciated counter-cyclical business, such as our Buy-rated Evercore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>), and companies with the potential to gain market share, which includes all four mentioned.
In particular, he anticipates a strong trading environment to support HOOD and IBKR, while HLI should experience through-the-cycle growth from ongoing momentum in Corporate Finance and benefits from restructuring and inorganic growth execution.
Yaro forecasts EVR to deliver best-in-class revenue growth from 2025 to 2027 and sees potential upside for EVR through its exposure to Equity Capital Markets (ECM).
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45415288/coinbase-ceo-brian-armstrong-invites-doge-staff-to-create-a-more-efficient-financial-system" target="_blank" rel="noreferrer noopener">Coinbase CEO Brian Armstrong Invites DOGE Staff To &#8216;Create A More Efficient Financial System&#8217;</a></li>
</ul>
Photo: Shutterstock

HOOD

IBKR

Analyst Predicts Double-Digit Revenue Growth For Retail Brokers, Noting Weak M&A, ECM/DCM Volumes In Investment Banking Sector

AppLovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares are down 2.8% to $366.06 on Thursday but remain up nearly 50% over the past month, as investors might be taking profits following a sharp post-earnings rally.
What To Know: The pullback comes after the stock <a href="https://www.benzinga.com/news/25/05/45380609/applovin-stock-surges-on-strong-q1-earnings-and-tariff-truce-tailwinds">surged</a> over the past week, fueled by better-than-expected first-quarter results and a broader tech rally sparked by <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation">easing</a> U.S.-China trade tensions.
Last Wednesday, AppLovin <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45323056/applovins-rapid-ad-growth-ai-gains-drive-hike-in-analyst-price-forecast">reported</a> first-quarter revenue of $1.48 billion, beating consensus estimates of $1.38 billion and growing 40% year-over-year. Adjusted EPS of $1.67 also topped forecasts.
Read Also: <a href="https://www.benzinga.com/news/25/05/45445582/plug-power-stock-hits-a-new-52-week-low-whats-going-on">Plug Power Stock Hits A New 52-Week Low: What&#8217;s Going On?</a>
The advertising segment led performance with 71% revenue growth and record 81% EBITDA margins. The company guided second-quarter ad revenue to $1.195–$1.215 billion and adjusted EBITDA to $970M–$990M, well above Street expectations.
Analysts <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45323056/applovins-rapid-ad-growth-ai-gains-drive-hike-in-analyst-price-forecast">responded</a> favorably. BofA reiterated a Buy with a $580 target, while Goldman Sachs and JPMorgan raised targets to $435 and $355, respectively.
Macro conditions have added some support this week, with Monday's news of a 90-day U.S.-China tariff rollback easing recession and inflation fears. April CPI data released Tuesday showed inflation cooling slightly, reinforcing market optimism.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020">Tariffs Slow Retail Spending As Producer Prices Post Sharpest Drop Since 2020</a>
<h2 class="wp-block-heading">How To Buy APP Stock</h2>
By now you're likely curious about how to participate in the market for AppLovin &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of AppLovin, which is trading at $366.06 as of publishing time, $100 would buy you 0.27 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, APP has a 52-week high of $525.04 and a 52-week low of $60.67.

AppLovin (APP) Stock Pulls Back Following Recent 50% Surge: What's Going On?

It is that time again.
13Fs are beginning to flow into the SEC offices, and the mojo wires are burning up with media types and the Instant Experts of the Internet psychoanalyzing what Warren Buffett, Bill Ackman, and Cathie Wood have been buying and selling.
I do not care what they are doing.
There are millions of eyeballs following every move of the best-known investors, which will leave little opportunity for gaining useful insights or creating an edge.
For the next several days, all the crackerjack-box Nuclear Engineers and global trade experts of Twitter will be experts in the reasons and beliefs that drive Warren and Bill to buy what they bought and sell what they sold.
I would rather follow those investors that are out of the limelight putting up steady returns that crush the markets and avoid the spotlight.
Being one of a small handful of people stealing ideas from a brilliant investor can still create a meaningful edge.
Robotti and Company is a great example of an out-of-the-limelight investment firm that has been quietly beating the market for decades. It is worth the time to go through the quarterly filings and see what gems we can uncover.
The Thundering Herd of the Web will not be in front of you and bid the shares up several points before you can finish your search.
They are not a hot money shop that owns the market darlings of the day and hold stocks for a long time, so most of you reading this will also ignore them.
Very few people active in the markets today will care for Robotti&#8217;s five-year average holding period.
When it comes to finding true value in the markets, few have demonstrated the consistent discipline and unwavering commitment of Bob Robotti. What I&#8217;ve always admired about Robotti&#8217;s approach is that it isn&#8217;t flashy or complicated &#8211; it&#8217;s simply buying good businesses at bargain prices and having the patience to let the market eventually recognize their worth.
Robotti&#8217;s story is a perfect example of how focusing on fundamentals can build a successful investment career. After graduating from Bucknell University and earning his MBA in Accounting from Pace University, he started in public accounting. This might seem like an unlikely beginning for an investment legend, but those accounting skills would become the foundation of his analytical approach.
The turning point in Robotti&#8217;s career came during an audit assignment for Tweedy Browne, where conversations with Joe Reilly Sr. introduced him to value investing principles.
Think about that &#8211; while most young professionals were just trying to get their work done, Robotti was absorbing wisdom from a partner at one of the most respected value shops on Wall Street.
That&#8217;s how real investing education happens.
Before launching his own firm, Robotti cut his teeth as a vice president at Gabelli &amp; Company. Working alongside another value investing legend in Mario Gabelli surely sharpened his skills.
In 1983, Robotti partnered with Dan Eng to launch Robotti &amp; Eng, Inc. Their initial focus was uncovering undervalued opportunities in pink sheet equities.
This wasn&#8217;t glamorous work &#8211; they were digging through the market&#8217;s bargain bin while everyone else was chasing the hot stocks of the day.
The firm eventually evolved into Robotti &amp; Company, expanding their offerings while never abandoning their core value philosophy.
What&#8217;s remarkable about Robotti&#8217;s investment approach is its consistency. For over 40 years, he&#8217;s stuck to the classic Benjamin Graham principles that markets frequently misprice securities. While others chased quarterly estimates and momentum plays, Robotti focused on understanding businesses&#8217; normalized earnings power before the market caught on.
The lesson from Robotti&#8217;s career is straightforward: buy good businesses at bargain prices, focus on the long term, and ignore market noise. While everyone else is chasing the latest fad, deep value investors like Robotti quietly compound wealth year after year.
In a market dominated by AI, crypto, and whatever else CNBC is hyping this week, Robotti&#8217;s patient, disciplined approach is refreshing. Find businesses trading below intrinsic value, understand what the market is missing, and wait. That&#8217;s how real wealth is built in the stock market, and Bob Robotti has proven it for four decades.
Here are the top three largest purchases by Robotti and Company in the first quarter of 2025:
Tidewater Inc. (Ticker: TDW) is the global leader in offshore support vessels, serving the international energy industry with a fleet of workboats that transport crews, equipment, and supplies to offshore drilling platforms and production facilities. The company operates primarily in deepwater and harsh environment markets, with a presence in every major offshore basin, including the U.S. Gulf of Mexico, West Africa, the North Sea, and Southeast Asia.
Following a successful post-bankruptcy restructuring, Tidewater has refocused on disciplined capital allocation, maintaining one of the youngest and most capable fleets in the industry. With improving offshore exploration and production activity, tight vessel supply, and growing demand for high-spec tonnage, Tidewater is positioned to benefit from rising day rates and extended contract durations. The company has low leverage, strong free cash flow generation, and significant operating leverage as vessel utilization recovers, making it a compelling deep-value play for investors with a long-term horizon on offshore energy markets.
Robotti is obviously bullish on the offshore oil and gas business as he also was a buyer of SEACOR Marine Holdings (Ticker: SMHI).
SEACOR is one of those under-the-radar names that&#8217;s quietly critical to keeping the offshore energy world spinning. Based out of Houston, SEACOR runs a global fleet of support vessels—platform supply boats, fast crew movers, and liftboats that haul people, gear, and equipment out to oil rigs and wind installations all over the world. If something&#8217;s happening offshore, there&#8217;s a decent chance a SEACOR boat is nearby helping make it happen.
The business leans heavily into safety, reliability, and increasingly, greener operations. They&#8217;ve got a solid footprint in every major offshore basin, serving big-name oil companies, independents, and even the offshore wind crowd. It&#8217;s a gritty, asset-heavy business, but SEACOR&#8217;s diversified fleet and global reach give it staying power.
Legacy Housing Corporation (Ticker: LEGH) is one of those quietly solid businesses that doesn&#8217;t make a lot of headlines, but it keeps chugging along, making money and filling a real need. Headquartered in Bedford, Texas, Legacy is the fourth-largest manufacturer of mobile and tiny homes in the U.S., with a stronghold across the South.
They&#8217;ve been at it since 2005, and their model is pretty simple. They build affordable homes, sell them through a network of company stores and independent dealers, and offer financing so folks can actually afford them.
What sets Legacy apart is how integrated their business is. They manufacture the homes themselves, finance them, and even sell directly to communities and consumers. That vertical setup keeps margins healthy, and you can see it in the numbers.
While revenue dipped slightly in 2024 to $184 million, net income jumped over 13% to $61.6 million. That&#8217;s thanks to some smart moves on the finance side and keeping expenses under control.
In a world where affordable housing is in short supply and demand just keeps rising, Legacy Housing looks like a business that&#8217;s built to last and to keep throwing off cash along the way.
These three stocks will not be ranked at the top of today&#8217;s social media searches.
They will not get much, if any, airtime on CNBC or Fox Business.
They are, however, solid companies trading at bargain prices that could deliver huge gains over the next several years.

Opinion

LEGH

SMHI

Alpha Buying: Why Smart Money Is Moving Into Offshore and Affordable Housing

<a href="https://www.bloomberg.com/news/articles/2025-05-15/cvs-bids-for-rite-aid-stores-patient-files-in-pacific-northwest?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-15/cvs-bids-for-rite-aid-stores-patient-files-in-pacific-northwest?embedded-checkout=true</a>

General

'CVS Bids For Rite Aid Stores, Patient Files in Pacific Northwest'- Bloomberg

Oppenheimer analyst Colin Rusch maintains Aeva Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>) with a Outperform and raises the price target from $9 to $18.

Price Target

Analyst Ratings

AEVA

Oppenheimer Maintains Outperform on Aeva Technologies, Raises Price Target to $18

Oppenheimer analyst Jay Olson maintains Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) with a Outperform and lowers the price target from $80 to $65.

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

Oppenheimer Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $65

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is catching traders' attention again as its current price action closely resembles a major historical pattern that led to <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">explosive gains in the past</a>.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2282</td>
<td>-1.2%</td>
<td>+19.7%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001519</td>
<td>-2.9%</td>
<td>+9%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.00001396</td>
<td>+1.8%</td>
<td>+36.6%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Trader Tardigrade dubbed this setup "Dogecoin Super Cycle 2," suggesting DOGE is at a key accumulation phase similar to the lead-up before its massive 2021 rally. 
Drawing parallels to the 2014–2018 macro pattern, Tardigrade believes the current structure implies substantial upside in the coming months.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> repeats the macro chart pattern in 2014-2018 &#x1f525;<a href="https://twitter.com/search?q=%24Doge&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$Doge</a> <a href="https://t.co/IoUwomhopW">pic.twitter.com/IoUwomhopW</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1923015587145580923?ref_src=twsrc%5Etfw">May 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to Bitcoinsensus, DOGE has already <a href="https://x.com/Bitcoinsensus/status/1923004315431518255">broken</a> out of a falling wedge, a bullish continuation pattern, and is now consolidating within a bull flag. The next technical target is $0.305, based on the measured move from the wedge breakout.
Similarly, Bluntz Capital <a href="https://x.com/Bluntz_Capital/status/1922845477512372626">remains</a> bullish, noting a classic inverse head and shoulders pattern with strong breakout volume. 
The ongoing pullback, he said, is healthy and could set the stage for further upside.
Statistics: Coinglass data shows Dogecoin liquidations in the past 24 hours stands at $13.4 million with long liquidations of $10.7 million. Open interest spiked to $3.03 billion.
Community News: In a recent post, 21Shares <a href="https://x.com/21Shares/status/1923021667254542341">highlighted</a> Dogecoin's cultural relevance, noting it "captures the spirit of the internet—from powering payments to supporting global causes."
The 21Shares Dogecoin ETP currently manages $2.15 million in assets, with a NAV of $7.66 as of May 14. The fund has returned 53.3% YTD, with a 2.2% daily gain.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45348013/dogecoin-jumps-4-can-doge-hit-1-soon">Dogecoin Jumps 4%: Can DOGE Hit $1 Soon?</a></li>
</ul>
Image: Shutterstock

$DOGE

$PEPE

$SHIB

Dogecoin Down 1% But This Pattern Signals A Breakout Is Imminent

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent&#xAE; (alirocumab) from competing in the market
Jury awarded Regeneron $135.6 million dollars of compensatory damages and $271.2 million dollars in punitive damages
TARRYTOWN, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) applauds the jury verdict in the U.S. District Court for the District of Delaware that found that Amgen Inc. violated antitrust and tort laws by creating a bundling scheme that illegally leveraged its blockbuster anti-inflammatory drugs Enbrel&#xAE; (etanercept) and Otezla&#xAE; (apremilast) to convince pharmacy benefit managers (PBMs) to select Repatha&#xAE; (evolocumab) as the exclusive PCSK9 category product over Praluent&#xAE; (alirocumab). The jury found that Amgen violated the Clayton Act, the Sherman Act, the New York State Donnelly Act, the California Cartwright Act and Delaware tort law.
Enbrel and Otezla are therapeutically different medicines that do not treat the heart conditions that Praluent or Repatha address. Amgen threatened to withhold rebates unless PBMs preferred Repatha and excluded Praluent. Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 marketplace, not based on clinical merit or price. Because of Amgen's size and unrelated product portfolio, their anticompetitive actions ultimately hurt competition and patients.
The jury awarded Regeneron $135.6 million dollars of compensatory damages. The jury also awarded Regeneron $271.2 million dollars in punitive damages. Punitive damages may be awarded to punish a party for outrageous conduct and deter a party, and others like it, from engaging in similar conduct in the future.

REGN

Regeneron Pharma: Federal Court Jury Found Amgen Liable For Violating Antitrust And Tort Laws By Using Cross-Therapeutic Bundled Rebates To Prevent Praluent From Competing In Market; Jury Awarded Regeneron $135.6M Of Compensatory Damages And $271.2M In Punitive Damages

Needham analyst Mike Matson maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and raises the price target from $100 to $108.

MMSI

Needham Maintains Buy on Merit Medical Systems, Raises Price Target to $108

Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with a Outperform and lowers the price target from $26 to $25.

ALMS

Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $25

Oppenheimer analyst Tyler Batory maintains Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) with a Outperform and lowers the price target from $165 to $155.

Oppenheimer Maintains Outperform on Toll Brothers, Lowers Price Target to $155

WIIM

IXHL

IXHL stock has given up its prior gain. Incannex Healthcare shares were trading highera fter the company reported a year-over-year increase in Q3 EPS results.

B. Riley Securities analyst Yuan Zhi maintains Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) with a Buy and lowers the price target from $1.2 to $1.

HYPR

B. Riley Securities Maintains Buy on Hyperfine, Lowers Price Target to $1

CMS Energy Announces New Corporate Organizational Structure To Support Operational Transformation And Long-Term Company Strategy

NWTG

NWTG stock has given up its prior gain. Newton Golf Company shares were trading higher after the company reported a year-over-year increase in Q1 financial results.

B. Riley Securities analyst Lucas Pipes maintains Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) with a Buy and lowers the price target from $183 to $181.

B. Riley Securities Maintains Buy on Alpha Metallurgical, Lowers Price Target to $181

<a href="https://www.benzinga.com/personal-finance/25/05/45192749/ray-dalio-says-chasing-wealth-without-purpose-is-a-tragedy-dont-make-money-itself-the-goal">Ray Dalio</a>'s Bridgewater Associates just made a massive portfolio move that's bound to raise eyebrows <a href="https://www.benzinga.com/quote/SPY/news" target="_blank" rel="noreferrer noopener">on Wall Street</a>. 
<h2 class="wp-block-heading">Is Berkshire&#8217;s Portfolio Sending A Message</h2>
According to its first quarter <a href="https://www.sec.gov/Archives/edgar/data/1350694/000117266125001828/xslForm13F_X02/primary_doc.xml">13F filin</a>g, the world's largest hedge fund slashed its top holding — the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — by nearly 60%, dumping 4.9 million shares. The fund still holds over 3.3 million SPY shares, but the dramatic trim slashed its portfolio weighting from 22.1% to just 8.7%.
It didn't stop there. Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) all got haircuts, with share reductions of 18.7%, 31.5%, and 16% respectively. These aren't minor trims — they're deliberate signals. 
Dalio may no longer be Bridgewater's CEO, but his macro fingerprints still linger in the firm's playbook.
Read Also: <a href="https://www.benzinga.com/25/05/45442127/palantir-soars-500-in-a-year-while-unitedhealth-tanks-40-tech-leaves-healthcare-in-the-dust">Palantir Soars 500% In A Year While UnitedHealth Tanks 40% — Tech Leaves Healthcare In The Dust</a>
<h2 class="wp-block-heading">Gold In, Tech Out?</h2>
If there's a pivot in the air, it's sparkling — Bridgewater added a fresh position in SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), which now ranks in its top ten holdings. Combined with fresh buying in Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#NYSE">BABAF</a>) and a double-down in emerging markets via the iShares Core MSCI Emerging Markets ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEMG#NYSE">IEMG</a>), the shift feels tactical — away from frothy U.S. equities, toward value, hedges, and international exposure.
Interestingly, while SPY took a hit, its ETF cousins iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>) and IEMG saw inflows. It's not a total U.S. equity exodus — it's a reallocation. And that's a warning worth watching.
For holders of SPY, IVV, and VOO, the message is mixed. While SPY got snipped, IVV was topped up. Bridgewater's moves suggest caution, not panic — but if Dalio's reading tea leaves, he's seeing clouds.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45445101/rout-to-rally-sp-500-stages-fastest-flip-in-market-history-with-22-comeback">Rout To Rally: S&amp;P 500 Stages Fastest Flip In Market History With 22% Comeback</a></li>
</ul>
Image: Shutterstock

Hedge Funds

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

GOOG

GOOGL

IEMG

NVDA

Ray Dalio's Bridgewater Dumps SPY, Trims Nvidia, Meta, Alphabet — Bearish Vibes?

Press Releases

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Health Care

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Peraso Inc. (NASDAQ: PRSO): A Critical Enabler Positioned for AI, 5G, and Telecom Growth – More Stock Pure-Plays inside….

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement

Spartan Capital Securities, LLC Announces Key February Transactions

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on "Global Transformation in Oral Medicine"

Comments

Lipella Pharmaceuticals

Lipella Pharmaceuticals (LIPO) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL